Literature DB >> 1376694

Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects.

G M Nichol1, B J O'Connor, J M Lecomte, K F Chung, P J Barnes.   

Abstract

We determined the effect of an inhibitor of neutral endopeptidase, acetorphan, on the skin responses to substance P and on the bronchostrictor effects of sodium metabisulphite aerosol in asthmatic subjects. One hour following ingestion of acetorphan (200 mg) or placebo tablets, cutaneous responses to substance P were performed in four subjects. In seven subjects, bronchial challenge with increasing concentrations of sodium metabisulphite solutions was performed and the concentration required to cause a 20% fall in baseline FEV1 determined (PC20). On the acetorphan day, there was a significant increase in the wheal and flare responses to substance P and to the diluent (0.9% NaCl) alone. However, there was no significant effect of acetorphan on the PC20 metabisulphite. We conclude that metabisulphite airway challenge in vivo may not invoke the release of endogenous neuropeptides. However, the degree of inhibition of neuropeptide breakdown by the oral dose of acetorphan used may not have been optimal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376694     DOI: 10.1007/bf00314856

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects.

Authors:  G Joos; R Pauwels; M van der Straeten
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

2.  Neutral endopeptidase modulates tachykinin-induced increase in vascular permeability in guinea pig skin.

Authors:  I Iwamoto; I F Ueki; D B Borson; J A Nadel
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

3.  Potentiation of the contractile effects of neuropeptides in human bronchus by an enkephalinase inhibitor.

Authors:  J L Black; P R Johnson; C L Armour
Journal:  Pulm Pharmacol       Date:  1988

4.  Effects of aerosolised substance P on lung resistance in guinea-pigs: a comparison between inhibition of neutral endopeptidase and angiotensin-converting enzyme.

Authors:  J O Lötvall; B E Skoogh; P J Barnes; K F Chung
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

5.  The effect of local converting enzyme inhibition on the dilator response to substance P in the human forearm.

Authors:  N Benjamin; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

6.  Catabolism of gastrin releasing peptide and substance P by gastric membrane-bound peptidases.

Authors:  N W Bunnett; R Kobayashi; M S Orloff; J R Reeve; A J Turner; J H Walsh
Journal:  Peptides       Date:  1985 Mar-Apr       Impact factor: 3.750

7.  Asthma as an axon reflex.

Authors:  P J Barnes
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

8.  Neutral metalloendopeptidase in human lung tissue and cultured cells.

Authors:  A R Johnson; J Ashton; W W Schulz; E G Erdös
Journal:  Am Rev Respir Dis       Date:  1985-09

9.  Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides.

Authors:  J T Gafford; R A Skidgel; E G Erdös; L B Hersh
Journal:  Biochemistry       Date:  1983-06-21       Impact factor: 3.162

10.  Effect of substance P on cardiovascular and respiratory function in subjects.

Authors:  R W Fuller; D L Maxwell; C M Dixon; G P McGregor; V F Barnes; S R Bloom; P J Barnes
Journal:  J Appl Physiol (1985)       Date:  1987-04
View more
  2 in total

Review 1.  A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis.

Authors:  J A Karlsson
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

2.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.